BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB:BVAXF) CEO James Passin tells Proactive the group is progressing its two most advanced vaccine programs in ovarian cancer and in COVID-19.
Passin says for its ovarian cancer vaccine, the group is preparing for a Phase 1 compassionate-use trial in the EU in 2022. Meanwhile, it recently conducted a 'very successful' animal study, demonstrating a 96.4% efficacy for antibodies for its coronavirus vaccine. The group is also working on its coronavirus detection technology.